F. P. Pérez Manghi

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.

J. Buse, P. Norwood, I. Lingvay, 2016, JAMA.

The vacuum cleft sign: an uncommon radiological sign

F. P. Pérez Manghi, J. Zanchetta, M. Sarli, 2005, Osteoporosis International.

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

J. Rosenstock, M. Davies, J. Frias, 2021, The New England journal of medicine.

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

G. Umpierrez, V. Pechtner, F. P. Pérez Manghi, 2014, Diabetes Care.

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)

Honghua H. Jiang, J. Fahrbach, K. Dungan, 2016, Diabetes, obesity & metabolism.

23. Insulin Degludec/Liraglutide (IDegLira) Is Superior to Insulin Glargine (IG) in A1c Reduction, Risk of Hypoglycemia, and Weight Change: DUAL V Study (166-OR)

J. Buse, P. Norwood, I. Lingvay, 2015, Nederlands Tijdschrift voor Diabetologie.